RPS calls for changes in research of controlled drugs
The Royal Pharmaceutical Society has responded to a consultation from the Advisory Council on the Misuse of Drugs regarding the legal constraints on researching controlled drugs.
In the response, we call for barriers that restrict legitimate research with controlled drugs, other than synthetic cannabinoids, to be removed. We’ve also highlighted that allowing flexibility around licensing, storage, formulation and the clinical supply of controlled drugs would facilitate more fundamental research to occur in the UK. RPS Chief Scientist Professor Gino Martini said:
“The UK is a world-leader in the life sciences sector. It’s important we’re given the best opportunity to support the development of new medicines that can help patients get the treatment that they need. We need to make the most of our incredible pharmaceutical infrastructure and ensure it’s easier to gain licences for the research of controlled drugs, which ultimately can help to enhance patient care.”
More information on our consultation response : Call for Evidence – Barriers to research for controlled drugs.